Immunomodulating Therapies in Type 1 Diabetes

Michael Quartuccio, M.D., Clare J. Lee, M.D., MHS, Thomas Donner, M.D.
Immunomodulating Therapies in Type 1 Diabetes is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

DEFINITION

  • Type 1 diabetes mellitus (T1DM) is an autoimmune disease.
  • Destruction of insulin producing beta-cells by T cells renders patients insulin-deficient.
  • Exogenous insulin is therefore required for T1DM management of hyperglycemia and to prevent ketoacidosis[19].
  • Several immunomodulating therapies have been investigated in research studies over the last decades with the goal of preventing, postponing or reversing the onset of T1DM by slowing or stopping the immune-mediated destruction of beta-cells.

-- To view the remaining sections of this topic, please or --

DEFINITION

  • Type 1 diabetes mellitus (T1DM) is an autoimmune disease.
  • Destruction of insulin producing beta-cells by T cells renders patients insulin-deficient.
  • Exogenous insulin is therefore required for T1DM management of hyperglycemia and to prevent ketoacidosis[19].
  • Several immunomodulating therapies have been investigated in research studies over the last decades with the goal of preventing, postponing or reversing the onset of T1DM by slowing or stopping the immune-mediated destruction of beta-cells.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: September 4, 2017